[A22-36] Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) – Addendum to Commission A21-145

Last updated 05.05.2022

Project no.:
A22-36

Commission:
Commission awarded on 30.03.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumours express PD-L1 (combined positive score ≥ 10) and who have not received prior chemotherapy for metastatic disease

Result of dossier assessment:

Unchanged after addendum: Hint of non-quantifiable added benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Project no. Title Status
A21-145 Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V Commission completed
A24-46 Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V Commission completed
A24-47 Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V Commission completed
A22-70 Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V Commission completed
A22-71 Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V Commission completed
A22-79 Pembrolizumab (bile cancer) – Benefit assessment according to § 35a SGB V Commission completed
A22-78 Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-77 Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-76 Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-75 Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V Commission completed
A22-73 Pembrolizumab (melanoma, advanced) – Benefit assessment according to § 35a SGB V Commission completed
A22-72 Pembrolizumab (melanoma, adjuvant) – Benefit assessment according to § 35a SGB V Commission completed

Federal Joint Committee (G-BA)

2022-05-05 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form